<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845178</url>
  </required_header>
  <id_info>
    <org_study_id>ABP-20001</org_study_id>
    <nct_id>NCT04845178</nct_id>
  </id_info>
  <brief_title>Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEON Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AEON Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention&#xD;
      in adults who suffer from six or more migraine days per month. The study will enroll 690&#xD;
      patients across approximately 60 sites in the United States, Canada and Australia. Study&#xD;
      subjects will be divided evenly across a low dose group, a high dose group and a placebo&#xD;
      group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the&#xD;
      Company's novel injection paradigm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in&#xD;
      adults who suffer from six or more migraine days per month. The study will enroll 690&#xD;
      patients across approximately 60 sites in the United States, Canada and Australia. Study&#xD;
      subjects will be divided evenly across a low dose of ABP-450 group, a high dose of ABP-450&#xD;
      group, and a placebo group. All patients will receive two treatment cycles utilizing the&#xD;
      Company's novel treatment paradigm involving fewer injections than the current botulinum&#xD;
      toxin treatment option for chronic migraine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Approximately 690 patients will be randomized in a 1:1:1 ratio and receive 1 of the following 3 treatments: ABP-450 Low Dose, ABP-450 High Dose, or placebo via intramuscular injection into pre-specified areas of the head and neck.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator, study nurse/other study personnel, and patients will be blinded to the treatment group. An appropriately trained person will reconstitute investigational product, fill masked-labeled syringes and provide them to the investigator, but will not perform any assessments with the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>The primary safety endpoint will be the incidence of TEAEs throughout the study when dosed with placebo, ABP-450 (low dose), or ABP-450 (high dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Monthly Migraine Days</measure>
    <time_frame>Baseline to Weeks 20 to 24 Treatment period.</time_frame>
    <description>The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from the 4-week Baseline period to Weeks 20 to 24 Treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Percentage of Participants with Suicidal Ideation and Behaviors will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Anti-Drug Antibodies (ADA) to ABP-450</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Percentage of patients developing Anti-Drug Antibodies to ABP-450 antibodies (binding and if positive, neutralizing) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Reduction in Mean Migraine Days (MMD)</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Percentage of patients with a reduction from Baseline of ≥ 50 percent, ≥ 75 percent and 100% percent in average number of MMD will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Monthly Migraine Days (MMD)</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Overall mean change from Baseline in the number of MMD will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Monthly Migraine Days (MMD) requiring medications for acute treatment of migraine or headaches</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Overall mean change from Baseline in number of MMD requiring migraine specific medication and non-specific medications for the acute treatment of migraine or headache will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Headache Hours</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Overall mean change from Baseline in headache (either moderate or severe) hours will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Monthly Headache Days</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Overall mean change from Baseline in monthly headache days will be assessed by Treatment Group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean change of Migraine-Specific-Quality of Life (MSQ) Domaines</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>The Mean Change in Migraine-Specific-Quality of Life (MSQ), a14-item assessment, with each item rated on a 6-point scale (ranging from &quot;none of the time&quot; to &quot;all of the time&quot;) with higher scores indicating better quality of life will be assessed by Treatment Group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Patient Global Impression of Change (PGI-C) Score</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>The Mean change in the subject's assessment of the change in clinical status since the start of treatment measured by the Patients' Global Impression of Change (PGI-C) Scale will be assessed by Treatment Group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in Patient Global Impression of Severity (PGI-S) Score</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>The Mean change in the subject's assessment of the severity of their condition since the start of treatment measured by the Patients' Global Impression of Severity (PGI-S) Scale will be assessed by Treatment Group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change in MIgraine Disability Assessment Score (MIDAS) Total Score</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>The Mean Change in the Migraine Disability Assessment Scale (MIDAS) between Baseline and End of Treatment assessed by Treatment Group. MIDAS is a 5-item self-administered questionnaire. The 5 items sum to a total MIDAS score of 0 to 155. A higher score indicates greater headache-related disability (worse score).</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patients with Reduction in Migraine Physical Function Impact Diary (MPFID)</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Percentage of patients with a reduction from Baseline in the impact on Migraine Physical Function Impact Diary (MPFID) will be assessed by Treatment Group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patients with Reduction in the Physical Impairment Domaine Score of the Migraine Physical Function Impact Diary (MPFID)</measure>
    <time_frame>Baseline to Week 28 - End of Study.</time_frame>
    <description>Percentage of patients with a reduction from Baseline on Physical Impairment Domain Score measured by Migraine Physical Function Impact Diary (MPFID) assessed by Treatment Group.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">690</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>ABP-450 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-450 Low Dose - intramuscular injections into specified muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP-450 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABP-450 High Dose - intramuscular injections into specified muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur) intramuscular injections into specified muscles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP-450</intervention_name>
    <description>ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.</description>
    <arm_group_label>ABP-450 - High Dose</arm_group_label>
    <arm_group_label>ABP-450 - Low Dose</arm_group_label>
    <other_name>prabotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride, sterile, unpreserved, USP/PhEur</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient can understand the eICF, provides signed eICF and patient privacy information&#xD;
             (eg, Authorization for Use and Release of Health and Research Study Information)&#xD;
             before initiating any study-specific procedure, and agrees to comply with protocol&#xD;
             requirements.&#xD;
&#xD;
          2. Male or female patients 18 years or older of age (no upper age limit) at the time of&#xD;
             signing the informed consent.&#xD;
&#xD;
          3. Patient has at least a 1-year history of episodic migraine (with or without aura) or&#xD;
             chronic migraine (with or without aura) according to the ICHD-3 (2018) definition and&#xD;
             diagnostic criteria.&#xD;
&#xD;
          4. Age of the patient at the time of migraine onset &lt;50 years.&#xD;
&#xD;
          5. History of, on average ≥6 migraine or probable migraine days per month in the 3 months&#xD;
             prior to Screening.&#xD;
&#xD;
          6. Patient is on a stable dose of medications, if any, as recommended by the patient's&#xD;
             health care practitioner, used for acute treatment of migraine for at least 3 months&#xD;
             prior to Screening. Patient is not taking any migraine prophylactic treatment&#xD;
             prohibited per protocol or if on prophylactic treatment has washed out.&#xD;
&#xD;
          7. A Woman of Child Bearing Potential (WOCBP) must be willing and able to use a medically&#xD;
             acceptable and effective method of birth control as determined by the investigator,&#xD;
             during the entire study.&#xD;
&#xD;
          8. A WOCBP must have a negative pregnancy test at Screening.&#xD;
&#xD;
          9. Patient is able to read, understand, and complete the eDiary.&#xD;
&#xD;
         10. Patient is willing and able to adhere to the study assessments, visit schedules, and&#xD;
             prohibitions, as described in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. History of migraine accompanied by diplopia or decreased level of consciousness, or&#xD;
             retinal migraine.&#xD;
&#xD;
          2. Current diagnosis of chronic tension-type headache, new persistent daily headache,&#xD;
             trigeminal autonomic cephalgia (eg, cluster headache), or cranial neuropathy.&#xD;
&#xD;
          3. Confounding and clinically significant pain syndromes (eg, fibromyalgia, chronic low&#xD;
             back pain, complex regional pain syndromes) as evaluated by the investigator.&#xD;
&#xD;
          4. Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,&#xD;
             or any other significant neuromuscular disease that might interfere with the study.&#xD;
&#xD;
          5. Psychiatric conditions that are uncontrolled and/or untreated, including conditions&#xD;
             that are not controlled for a minimum of 6 months prior to Screening as evaluated by&#xD;
             the investigator. Patients with a lifetime history of psychosis, mania, or dementia&#xD;
             are excluded.&#xD;
&#xD;
          6. History of addiction, including alcohol or drugs of abuse, within 6 months prior to&#xD;
             Screening.&#xD;
&#xD;
          7. Hepatitis B (HBsAg positive) or hepatitis C (ie, detectable HCV RNA) virus infection.&#xD;
&#xD;
             Note: Patients with a prior history of treated hepatitis B virus infection who are&#xD;
             antigen negative or patients with a prior history of treated HCV infection who are HCV&#xD;
             RNA undetectable may be considered after consultation with the study medical monitor.&#xD;
&#xD;
          8. Any infection or clinically significant skin problem in any of the injection sites.&#xD;
&#xD;
          9. Have been injected with anesthesia or steroids in the targeted muscles during the 30&#xD;
             days immediately prior to initiation of the Baseline period (Section 5.8.1).&#xD;
&#xD;
         10. Any medical condition (including but not limited to viral or other active infections)&#xD;
             that, in the opinion of the investigator, classifies the patient as unsuitable for&#xD;
             participation in the study or patients who do not seem to be in good general health at&#xD;
             the time of Screening, and prior to any investigational study drug administration.&#xD;
&#xD;
             Note: Patients will not routinely be tested for COVID-19 during the study. Patients&#xD;
             presenting with fever or who are symptomatic for COVID-19 will be required to be&#xD;
             tested and treated through their general practitioner.&#xD;
&#xD;
             Other Diagnostic Assessments&#xD;
&#xD;
         11. Significant risk of self-harm based on clinical interview and responses on the C-SSRS,&#xD;
             or of harm to others in the opinion of the investigator; patients must be excluded if&#xD;
             they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on&#xD;
             the C-SSRS) in the past 6 months or report suicidal behavior in the past 6 months&#xD;
             prior to Screening.&#xD;
&#xD;
         12. Body mass index ≥38 kg/m2 at Screening.&#xD;
&#xD;
         13. Use of opioids or barbiturates &gt;2 days per month in the 3 months prior to Screening.&#xD;
&#xD;
         14. Use of CBD or other types of cannabinoids in the 3 months prior to Screening and&#xD;
             throughout the study.&#xD;
&#xD;
         15. Any use of botulinum toxin for migraine or any other medical reasons within 4 months&#xD;
             prior to Screening and during the Screening and Baseline periods.&#xD;
&#xD;
         16. Any monoclonal antibody CGRP inhibitor treatment (within or outside of a clinical&#xD;
             study) within 6 months prior to Screening and throughout the study.&#xD;
&#xD;
         17. Any orally administered non-peptide CGRP antagonists (within or outside of a clinical&#xD;
             study) within 4 weeks prior to the Baseline period and throughout the study.&#xD;
&#xD;
         18. Use of devices for the treatment of migraine (ie, non-invasive neuromodulation&#xD;
             therapies including but not limited to non-invasive nerve stimulation [gammaCore],&#xD;
             transcranial magnetic stimulation [cephaly], external trigeminal nerve stimulation,&#xD;
             transcutaneous electrical nerve stimulation, and peripheral neuroelectrical&#xD;
             stimulation) during Screening and throughout the study.&#xD;
&#xD;
         19. Any other treatments or therapies (eg, acupuncture in head and neck region, cranial&#xD;
             traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and&#xD;
             dental splints for headache) to the head, neck, or shoulder regions during Screening&#xD;
             and throughout the study that, in the opinion of the investigator, would interfere&#xD;
             with the investigational study drug.&#xD;
&#xD;
         20. History of inadequate response to 3 classes of medications (which have different&#xD;
             mechanisms of action) prescribed for the prevention of migraine, excluding CGRP&#xD;
             therapies.&#xD;
&#xD;
         21. History of hypersensitivity to human serum albumin, sucrose, or botulinum toxin type A&#xD;
             or a positive test for botulinum toxin type A antibody.&#xD;
&#xD;
         22. Participation in another interventional study within 6 months prior to Screening and&#xD;
             throughout the study.&#xD;
&#xD;
             Prior/Concomitant Medications and Treatments&#xD;
&#xD;
         23. Female patients planning on becoming pregnant during the course of the study and/or&#xD;
             lactating/breastfeeding.&#xD;
&#xD;
         24. Patient has donated or lost a significant volume (&gt;450 mL) of blood or plasma within&#xD;
             30 days of screening.&#xD;
&#xD;
         25. Patient is an employee or family member of the investigator, study site personnel,&#xD;
             PPD, or AEON.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard B Lipton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stewart J Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Del Stagg, PhD</last_name>
    <phone>949-354-6424</phone>
    <email>ds@aeonbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MDFirst Research</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Mitchell</last_name>
      <phone>480-508-1038</phone>
      <email>ctcchandler@mdfirstresearch.com</email>
    </contact>
    <investigator>
      <last_name>Hemant Pandey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Ossino</last_name>
      <phone>602-788-3437</phone>
      <email>eliteclinicalstudies@cox.net</email>
    </contact>
    <investigator>
      <last_name>Joseph Lillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovation Medical Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Horton</last_name>
      <phone>602-482-2116</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Gitt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasha Marriott</last_name>
      <phone>602-759-7559</phone>
      <email>volunteer@crctrials.com</email>
    </contact>
    <investigator>
      <last_name>Corey Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center of Southern California, LLC</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guadalupe Sanchez</last_name>
      <phone>619-432-0954</phone>
    </contact>
    <investigator>
      <last_name>Jack Schim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axiom Research LLC</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela West</last_name>
      <phone>909-824-2325</phone>
      <email>info@axiomresearch.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Headache and Balance Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Kutka</last_name>
      <phone>559-435-6492</phone>
    </contact>
    <investigator>
      <last_name>Melvin Helm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates LLC</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Berg</last_name>
      <phone>909-792-9007</phone>
    </contact>
    <investigator>
      <last_name>Donald Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Hernandez-Lopez</last_name>
      <phone>858-278-3647</phone>
      <phone_ext>312</phone_ext>
    </contact>
    <investigator>
      <last_name>Stacey Layle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. George J Rederich, MD</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Roberts</last_name>
      <phone>310-376-9492</phone>
    </contact>
    <investigator>
      <last_name>George Rederich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Waves LLC - Hunt - PPDS</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Schulz</last_name>
      <phone>719-262-9283</phone>
    </contact>
    <investigator>
      <last_name>Gary Tarshis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Centers</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Arnett</last_name>
      <phone>303-463-1947</phone>
    </contact>
    <investigator>
      <last_name>Stanton Elzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Connecticut Research, LLC - ClinEdge - PPDS</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelley Sanok</last_name>
      <phone>860-437-7092</phone>
    </contact>
    <investigator>
      <last_name>Laurence Radin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marysol Castillo</last_name>
      <phone>305-441-6611</phone>
    </contact>
    <investigator>
      <last_name>Jose Carpio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canvas Clinical Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sosa Yamilet</last_name>
      <phone>561-229-0002</phone>
    </contact>
    <investigator>
      <last_name>Mario Guillen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioMed Research Institute, INC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efren Mendez</last_name>
      <phone>305-267-4123</phone>
      <email>emendez@biomedresearchinst.com</email>
    </contact>
    <investigator>
      <last_name>Guido Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Center, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gonzalez</last_name>
      <phone>305-846-7903</phone>
    </contact>
    <investigator>
      <last_name>Esperanza Arce Nunez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovation Medical Research Center</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janelly Mainade</last_name>
      <phone>305-300-2695</phone>
    </contact>
    <investigator>
      <last_name>Karen Figueredo-Reyes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Central Florida - ClinEdge - PPDS</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Morris-Ossinac</last_name>
      <phone>863-508-2256</phone>
    </contact>
    <investigator>
      <last_name>Mohammad Eldeeb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research Inc. - Clinedge - PPDS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Mackett</last_name>
      <phone>404-851-9934</phone>
    </contact>
    <investigator>
      <last_name>Matthews Gwynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drug Studies America, Inc</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Housley</last_name>
      <phone>678-581-5252</phone>
      <email>info@drugstudies.net</email>
    </contact>
    <investigator>
      <last_name>Marvin Tark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - Boise - ERN - PPDS</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinn DeYoung</last_name>
      <phone>208-377-8653</phone>
    </contact>
    <investigator>
      <last_name>Mark Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas Institute of Research, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nai-Yung Wesley</last_name>
      <phone>913-381-5225</phone>
      <phone_ext>475</phone_ext>
    </contact>
    <investigator>
      <last_name>Atul Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Clinical Solutions: Tandem Clinical Research, LLC - Clinedge - PPDS</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Odom</last_name>
      <phone>504-934-8424</phone>
    </contact>
    <investigator>
      <last_name>Adil Fatakia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Chow</last_name>
      <phone>617-477-4868</phone>
    </contact>
    <investigator>
      <last_name>Arkadiy Stolyar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute - Hunt - PPDS</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>40825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freddrenia Holmes</last_name>
      <phone>248-957-8940</phone>
    </contact>
    <investigator>
      <last_name>Aaron Ellenbogen, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Lakey</last_name>
      <phone>816-943-0770</phone>
      <email>newstudy@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>John Ervin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research, LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Rocco</last_name>
      <phone>636-387-5100</phone>
    </contact>
    <investigator>
      <last_name>Timothy Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Fenske</last_name>
      <phone>417-883-7889</phone>
      <email>info@clinvest.com</email>
    </contact>
    <investigator>
      <last_name>David True, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrett Clinic, P.C. - Clinedge - PPDS</name>
      <address>
        <city>La Vista</city>
        <state>Nebraska</state>
        <zip>68128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Workman</last_name>
      <phone>402-991-9500</phone>
      <email>info@barrettclinic.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Ahlers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Olan</last_name>
      <phone>402-934-0044</phone>
    </contact>
    <investigator>
      <last_name>Michael Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research - CRCN, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gass</last_name>
      <phone>702-893-8968</phone>
      <email>info@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute - ClinEdge - PPDS</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Schwartz</last_name>
      <phone>856-566-9000</phone>
    </contact>
    <investigator>
      <last_name>Michael Hassman, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials Inc - Clinedge - PPDS</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Duran-Gomez</last_name>
      <phone>505-224-2735</phone>
      <email>questions@abqct.com</email>
    </contact>
    <investigator>
      <last_name>Marigene Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Burgos</last_name>
      <phone>716-558-5670</phone>
    </contact>
    <investigator>
      <last_name>Laszlo Mechtler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates LLC</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryanne Watson</last_name>
      <phone>716-626-6320</phone>
    </contact>
    <investigator>
      <last_name>James Wild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Chapman</last_name>
      <phone>937-276-4311</phone>
    </contact>
    <investigator>
      <last_name>Martin Schear, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>META Medical Research Institute, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pournima Shirahatti</last_name>
      <phone>937-252-2000</phone>
      <phone_ext>383</phone_ext>
      <email>info@metamedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Priyesh Mehta, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Orthopedic Foundation</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Showe</last_name>
      <phone>614-533-5556</phone>
    </contact>
    <investigator>
      <last_name>Martin Taylor, DO, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Schultz</last_name>
      <phone>412-650-6155</phone>
    </contact>
    <investigator>
      <last_name>Nathan Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DCT - Baxter LLC dba Discovery Clinical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Trotty</last_name>
      <phone>214-377-0814</phone>
    </contact>
    <investigator>
      <last_name>Barbara Baxter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercury Clinical Research Incorporated</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David De Leon Garza</last_name>
      <phone>713-777-5343</phone>
    </contact>
    <investigator>
      <last_name>Shahin Shirzadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research LLC - Clinedge - PPDS</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaislee Ferris</last_name>
      <phone>801-356-5555</phone>
      <email>info@aspclinic.com</email>
    </contact>
    <investigator>
      <last_name>Jason Andersen, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>425-453-0404</phone>
    </contact>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual Participant Data collected during the trial, after deidentification may be shared following review of the clinical study report by the FDA review division and if a decision is made to publish the results in an publication outside posting the results in clinicaltrials.gov</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

